T. Rowe Price Associates
CELL

T. Rowe Price Associates’s PhenomeX Inc. Common Stock CELL Stock Holding History

T. Rowe Price Associates’s Portfolio CELL Stock Details CELL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-39,349
Closed -$280K – 3023
2022
Q1 		$280K Sell
39,349
-433,811
-92% -$3.59M ﹤0.01% 2575
2021
Q4 		$8.6M Buy
473,160
+55,430
+13% +$1.2M ﹤0.01% 1424
2021
Q3 		$8.17M Sell
417,730
-370,962
-47% -$14.1M ﹤0.01% 1444
2021
Q2 		$35.3M Sell
788,692
-278,997
-26% -$12.9M ﹤0.01% 1151
2021
Q1 		$53.6M Buy
1,067,689
+605,392
+131% +$41.3M 0.01% 980
2020
Q4 		$41.3M Sell
462,297
-4,941
-1% -$416K ﹤0.01% 1021
2020
Q3 		$35.7M Buy
+467,238
New +$29.7M ﹤0.01% 982

Other funds holding CELL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates's CELL Position: Q2 2022 in Review

T. Rowe Price Associates sold out of PhenomeX Inc. Common Stock (CELL) in Q2 2022, closing a stake of 39,349 shares — an estimated $280K sold.

T. Rowe Price Associates first reported a position in CELL in Q3 2020 and held it in 7 quarters. The position peaked at $53.6M in Q1 2021. 123 funds tracked by Wall St. Rank hold CELL as of Q2 2022.

  • T. Rowe Price Associates reported no remaining PhenomeX Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 39,349 PhenomeX Inc. Common Stock shares in Q2 2022, an estimated $280K.
  • T. Rowe Price Associates first reported a position in PhenomeX Inc. Common Stock in Q3 2020 and held it in 7 quarters.
  • T. Rowe Price Associates's PhenomeX Inc. Common Stock position peaked at $53.6M in Q1 2021.
  • 123 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q2 2022.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.